ACR/ARP 2019

News story | Guselkumab shows promise for PsA
Researcher comment | The DISCOVER-2 trial
Expert commentary | The DISCOVER trials

News story | TULIP-1 results fail to support phase II findings for anifrolumab in SLE
News story | TULIP-2 meets primary endpoint for anifrolumab efficacy in SLE

News story | Methotrexate plus glucocorticoids compare favorably with biologics in early RA
Researcher comment | The NORD-STAR trial

News story | Support for rituximab maintenance therapy in ANCA-associated vasculitis
Researcher comment | The RITAZAREM trial

News story | IL-17A inhibition may be beneficial for nonradiographic axSpA
News story | Secukinumab may represent a treatment option for nonradiographic axSpA
Expert commentary | The COAST-X trial

News story | Upadacitinib demonstrates potential for ankylosing spondylitis
Researcher comment | The SELECT-AXIS 1 trial

News story | Methotrexate disappoints in hand osteoarthritis trial
Researcher comment | THE ADEM trial
Expert commentary | The HOPE and ADEM trials

News story | Short-term prednisolone offers HOPE for painful hand osteoarthritis
Researcher comment | The HOPE trial
Expert commentary | The HOPE and ADEM trials

News story | Continuing ixekizumab superior to withdrawal for stable psoriatic arthritis patients
Researcher comment | The SPIRIT-P3 trial

Sangeeta Sule gives a pediatric rheumatologist’s view on a trial looking at tofacitinib for the treatment  of polyarticular juvenile idiopathic arthritis and the potential implementation of the results in the clinic (2:55).

Irene van der Horst Bruinsma discusses the dual benefits of certolizumab pegol for patients with axial spondyloarthritis and a history of acute anterior uveitis (3:32).

Watch more interviews with researchers and independent experts on clinical trials presented at ACR/ARP 2019.

Taking omega-3 is associated with a reduction in measures of rheumatoid arthritis disease activity, suggests real-world data.

Addition of the Bruton’s tyrosine kinase inhibitor fenebrutinib to standard care does not improve outcomes for patients with systemic lupus erythematosus, suggest findings from a phase II trial.

Telitacicept, a recombinant fusion protein targeting B-lymphocyte stimulator and the APRIL proliferation-inducing ligand, has shown potential for the treatment of systemic lupus erythematosus in a phase IIb trial conducted in China.